Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Patient Stories

Fabry Disease Stories


Hemophilia A Stories


Prion Stories


Renal Transplant Stories